A regional cohort associated baseline benzodiazepine use with all-cause mortality, an outcome broader than confirmed COVID-related death.
The cohort followed 79,083 adults aged at least 50 during March–June 2020. In multivariable analysis, recorded benzodiazepine use was associated with all-cause mortality, with a hazard ratio of 1.34 and a 95% confidence interval of 1.11–1.61.
The study separately examined deaths among people with laboratory-confirmed COVID-19. The all-cause estimate must not be relabeled as a benzodiazepine effect on COVID-specific mortality.
Medical burden, frailty, treatment indication, and unmeasured social factors can influence prescribing and death risk. Adjustment and subgroup analyses do not eliminate residual confounding. Early-pandemic testing and regional conditions also shape applicability.
For an individual assessment, the population association cannot establish the cause of death or prove simultaneous ingestion. The paper supports careful endpoint labeling and attention to baseline risk rather than a causal class-wide conclusion.
Original analysis of the supplied journal article, identified as PMC8493770.